Q1 2011 · —
Revenue$50.88M$50.88M ±0.0% vs Q1 2010−39.1% vs Q4 2010
Net Income$21.83M$21.83M ±0.0% vs Q1 2010−41.8% vs Q4 2010
EPS Diluted$0.48$0.48 ±0.0% vs Q1 2010−39.2% vs Q4 2010
Gross Profit$47,094,000±0.0%
Operating Income$22,604,000—
Operating Cash Flow$24,448,000—
Free Cash Flowderived$24,382,000—
Margins · derived
Gross margin92.6%±0.0 pt vs Q1 2010
Operating margin44.4%
Net margin42.9%±0.0 pt vs Q1 2010
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Revenue | $50.88M | $50.88M |
| Net Income | $21.83M | $21.83M |
| EPS Diluted | $0.48 | $0.48 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR